With the aging population and the three-year epidemic in China, people pay more and more attention to medical care, and the proportion of medical care in residents' consumption will be higher and higher in the future. Today I compiled a list of pharmaceutical stocks for your attention.

What are the names of pharmaceutical stocks?

1, Hengrui Pharma 600276: Hengrui Pharma Company is one of the largest research and production bases of anti-tumor drugs, surgical drugs and contrast agents in China. The company's products cover many fields, such as anti-tumor drugs, surgical anesthesia drugs, special infusion, contrast agents, cardiovascular drugs and so on.

2. Mindray Medical 300760: Shenzhen Mindray Biomedical Electronics Co., Ltd. is mainly engaged in research and development, manufacturing, marketing and service of medical devices. Its main products cover life information and support, in vitro diagnosis and medical imaging.

3. WuXi PharmaTech 603259: WuXi PharmaTech New Drug Development Co., Ltd. mainly provides all-round and integrated platform services for the discovery, R&D and production of small molecule chemicals, and provides all kinds of new drug R&D, production and supporting services to global pharmaceutical enterprises in the form of the whole industry chain platform.

4. Aier Ophthalmology 3000 15: Aier Ophthalmology Hospital Group Co., Ltd. is an ophthalmology medical institution, mainly engaged in the diagnosis and treatment of various ophthalmic diseases, surgical services and medical optometry.

Pien Tze Huang 600436: Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. is a company mainly engaged in the production and sales of tablets, granules and other pharmaceutical products and tourist commodities. The company's main products are Pien Tze Huang and its series products.

6. Yunnan Baiyao 000538: Yunnan Baiyao Group Co., Ltd. is a company mainly engaged in chemical raw materials, chemical preparations, Chinese patent medicines, Chinese herbal medicines and biological products.

According to normal analysis, the China stock market should show some performance this year, but the "grey rhinoceros" in the stock market should also pay attention to the nuclear war in the conflict between Russia and Ukraine, the Taiwan Strait war, the economic blockade of China by the United States, and the domestic economic recovery that is less than expected.

What are the list analysis of pharmaceutical stocks?

The SPDRETF (XLV), a health care selected sector of SPDR ETF, has fallen by 3.6% in 22 years, which is much better than the decline of S&P 500 index 19.4%.

CNBCPro screened the stocks in the ETF that were given a "buy" rating by more than 55% analysts, and the average price of these stocks increased by at least 20%.

CVS(CVS) is given a buy rating by 58% analysts, and its average target price means that there is 28% room for growth. The stock fell 9.7% last year, less than the market.

Earlier this week, CVS said that its annual EPS may reach the high end of the previous range, and its revenue will exceed previous expectations.

Dexcom(DXCM), a glucose monitor manufacturer, also issued positive guidelines, pointing out that the revenue in the fourth quarter will exceed the average expectations of analysts surveyed by FactSet.

Nearly three-fifths of analysts rate the stock as buy, and its average target price means nearly 22% upside. Like CVS, Dexcom outperformed the Standard & Poor's 500 Index, although the gap was small. The stock lost 15.6% in market value last year.

Bio-Techne(TECH) is one of the most hit stocks in the 22-year list, plunging 35.9%. But 2023 looks much better. 70% of analysts who follow the stock rate it as buy, and the average analyst expects the stock price to rebound by nearly 28% in the coming year.

TimothyDaley, an analyst at Wells Fargo, upgraded Bio-Techne's rating from underweight to held last week, and pointed out that "the valuation has been reset to a reasonable level, while the long-term growth prospects remain unchanged."

According to FactSet, as of Friday, UNH's revenue and earnings per share in the fourth quarter exceeded analysts' average expectations. The managed medical and insurance company also reiterated its earnings per share, income and cash flow forecast for the whole year of 2023.

About 75% of analysts who pay attention to UnitedHealth rate it as buy, and the average target price means that there is 20% room for growth. United health has increased by 5.6% in 22 years.

In 2023, the pharmaceutical manufacturing concept stocks are:

(1), Lotus shares:

Judging from the compound growth of revenue in the past three years, the company's compound growth of revenue in the past three years was -33.36%, the lowest revenue in the past three years was190,000 yuan, and the highest revenue in 20 years was 244 million yuan.

The industry has been changed to pharmaceutical industry.

In the past five trading days, the stock price rose by 8.35%, the highest price was 5.67 yuan, and the total market value rose by 65438+72 million.

(2) Renhe Pharmaceutical:

Judging from the compound growth of revenue in the past three years, the compound growth of revenue in the past three years is 3.8%, and the lowest revenue in the past three years is 4.278 billion yuan in 20 years and the highest is 2 1 year, 4.936 billion yuan.

The company belongs to the pharmaceutical manufacturing industry, which is subdivided into production and sales enterprises focusing on OTC products and big health products.

The share price rose by 2.43% in the past five days and by 1.67% in 2023.

(3) Yahong Medicine:

Judging from the compound growth of revenue in the past three years, the highest is 4,574.88 yuan 2 1 year.

In the past five trading days, the U period of Yahong Pharmaceutical rose by 2.94%, with the highest 16.98 yuan and the lowest 15.95 yuan, and the total market value increased by 279 million yuan.

(4), pharmaceutical industry:

Judging from the compound growth of revenue in the last three years, the compound growth of revenue in the last three years is -9.28%, and the lowest revenue in the last three years is 633 million yuan in 20 years and the highest is192 1 10,000 yuan in 9 years.

The company is engaged in pharmaceutical manufacturing, health care products production, medical equipment, daily necessities wholesale, technical services and house leasing.

In the past five trading days, the stock price rose by 7.9 1%, with the highest price of 24.5 1 yuan, and the total market value rose by 438 million.

(5) Cheng Nuo Jianhua:

Judging from the company's compound revenue growth in the past three years, the compound revenue growth in the past three years is 76,400%, with the lowest revenue of 654.38+654.38+0.247 million yuan in 2009 and the highest revenue of 2654.38+0.654.38+0.43 billion yuan.

Looking back on the past five trading days, Cheng Nuo Jianhua U fell for five consecutive days. During the period, the overall decline was 8.06%, with the highest price 14.83 yuan and the lowest price 14.32 yuan, with a total of 24,522,900 lots.